Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Biotech
Ultimovacs' cancer vaccine flunks another checkpoint combo test
After a series of delays, the biotech reported the failure of the melanoma study Thursday—and outlined plans to cut costs to keep going into 2025.
Nick Paul Taylor
Mar 7, 2024 6:14am
Replimune shares halve as skin cancer drug fails phase 2
Dec 5, 2023 10:35am
Kinnate lays off 70% of staff, pulls back from programs
Sep 19, 2023 6:00am
FDA resource constraints delay decision on Iovance cell therapy
Sep 15, 2023 5:20am
Long survival spurs Ultimovacs to mull ways to end cancer trial
Aug 22, 2023 10:00am
Merck, Moderna unveil phase 3 trial plan for mRNA cancer vaccine
Jul 10, 2023 5:00am